Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287988 · ClinicalTrials.gov registry record
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
A clinical trial, sponsored by ThromboGenics.
- Completed
- Registry status
- 24
- Enrollment target
NCT01287988 is a clinical trial that has completed, run by ThromboGenics. The registered enrollment target is 24 participants.
The verdict
NCT01287988 has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).
Interventions
- DRUG placebo
- DRUG ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287988
The ClinicalTrials.gov registry entry for NCT01287988 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01287988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01287988 about?
NCT01287988 is a clinical study titled "Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies". The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).
What is the current status of trial NCT01287988?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2011-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01287988?
The interventions under investigation include: placebo (DRUG), ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT01287988?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.